[go: up one dir, main page]

CL2018003452A1 - Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides. - Google Patents

Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides.

Info

Publication number
CL2018003452A1
CL2018003452A1 CL2018003452A CL2018003452A CL2018003452A1 CL 2018003452 A1 CL2018003452 A1 CL 2018003452A1 CL 2018003452 A CL2018003452 A CL 2018003452A CL 2018003452 A CL2018003452 A CL 2018003452A CL 2018003452 A1 CL2018003452 A1 CL 2018003452A1
Authority
CL
Chile
Prior art keywords
compositions
semi
excipients
cannabinoids
methods
Prior art date
Application number
CL2018003452A
Other languages
English (en)
Inventor
Nathan Bryson
Avinash Chander Sharma
Original Assignee
Acerus Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60478110&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018003452(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acerus Labs Inc filed Critical Acerus Labs Inc
Publication of CL2018003452A1 publication Critical patent/CL2018003452A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/577—Malvaceae (Mallow family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN CANNABINOIDES ADECUADAS PARA ADMINISTRACIÓN NASAL. LAS COMPOSICIONES COMPRENDEN LOS CANNABINOIDES MENCIONADOS ANTERIORMENTE Y LOS EXCIPIENTES SELECCIONADOS DE MANERA QUE LAS COMPOSICIONES SON LÍQUIDOS SEMISÓLIDOS O VISCOSOS. EN REALIZACIONES PREFERIDAS, EL CANNABINOIDE ES A9-TETRAHIDROCANNABINOL (THC) O CANNABIDIOL (CBD). LOS EXCIPIENTES SON PREFERIBLEMENTE UNA MEZCLA DE UN VEHÍCULO ACEITOSO (TAL COMO ACEITE DE RICINO O ACETATO DE SACAROSA ISOBUTIRATO) Y UN AGENTE HUMECTANTE / TENSIOACTIVO (COMO OLEOYIL POLIOXILGLICÉRIDOS). LAS COMPOSICIONES PUEDEN COMPRENDER ADEMÁS ESPESANTES (TALES COMO DIÓXIDO DE SILICIO) Y OTROS EXCIPIENTES. SE DESCRIBEN MÉTODOS PARA FABRICAR Y ADMINISTRAR LAS COMPOSICIONES, ASÍ COMO MÉTODOS PARA USAR LAS COMPOSICIONES EN EL TRATAMIENTO DE TRASTORNOS COMÚNMENTE CONOCIDOS POR SER AFECTADOS POR LOS CANNABINOIDES.
CL2018003452A 2016-06-02 2018-12-03 Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides. CL2018003452A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344486P 2016-06-02 2016-06-02
US201662426403P 2016-11-25 2016-11-25

Publications (1)

Publication Number Publication Date
CL2018003452A1 true CL2018003452A1 (es) 2019-06-21

Family

ID=60478110

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003452A CL2018003452A1 (es) 2016-06-02 2018-12-03 Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides.

Country Status (12)

Country Link
US (1) US20170348276A1 (es)
EP (1) EP3478270A4 (es)
KR (1) KR102433459B1 (es)
CN (1) CN109789090A (es)
BR (1) BR112018075073A2 (es)
CA (1) CA3026274A1 (es)
CL (1) CL2018003452A1 (es)
CO (1) CO2018013654A2 (es)
MX (1) MX392668B (es)
TW (1) TWI790204B (es)
UY (1) UY37271A (es)
WO (1) WO2017208072A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907823B1 (en) 2014-11-07 2018-03-06 Eric H. Kuhrts Water-soluble phytocannabinoid formulations
SI3687513T1 (sl) 2017-09-28 2022-04-29 Zynerba Pharmaceuticals, Inc. Zdravljenje sindroma fragilnega kromosoma X in avtizma s kanabidiolom
US20190240148A1 (en) * 2018-02-07 2019-08-08 Tarukino Holdings, Inc. Lubricant composition and method for preparing the composition
CA3092914A1 (en) * 2018-03-05 2019-09-12 Solva, Llc Water-soluble phytocannabinoid formulations
US11020357B2 (en) * 2018-03-19 2021-06-01 Alexandra Yerike Compound for use in relief of pain and method to produce thereof
EP3856172A4 (en) * 2018-09-28 2022-10-05 Visceral Therapeutics Inc. Pharmaceutically active cannabis-based compositions and methods of use for treating gastrointestinal conditions
US20200170962A1 (en) * 2018-11-30 2020-06-04 F. Markus Leweke Nasal cannabidiol compositions
CN113365635A (zh) * 2018-12-14 2021-09-07 阿克罗斯生物制药公司 睾酮的活性酯衍生物、组合物和其用途
KR20210104084A (ko) 2018-12-14 2021-08-24 지네르바 파마슈티컬스, 인코포레이티드 칸나비디올을 사용하는 22q11.2 결실 증후군의 치료
BR102018076973A2 (pt) * 2018-12-21 2020-09-15 Entourage Participações S.A. Composição farmacêutica compreendendo extrato de cannabis, produto farmacêutico, processo de preparação da dita composição
WO2020142692A1 (en) * 2019-01-04 2020-07-09 Columbia Care Llc Topical formulations having cannabinoid
US20200215024A1 (en) * 2019-01-08 2020-07-09 Replennabis LLC Cannabinoid formulations for treating alcohol hangover
BR112021014976A2 (pt) * 2019-02-08 2021-10-05 Schedule 1 Therapeutics, Inc. Composições compreendendo canabinoides e métodos de uso das mesmas
US10993928B2 (en) * 2019-04-26 2021-05-04 Natural Extraction Systems, LLC Compositions comprising non-crystalline forms of cannabidiol
US20220257560A1 (en) * 2019-05-23 2022-08-18 India Globalization Capital, Inc. Compositions and methods using cannabinoids for treating stammering/stuttering and symptoms of tourette syndrome
CN110433133A (zh) * 2019-08-19 2019-11-12 中国人民解放军军事科学院军事医学研究院 治疗创伤后应激障碍的大麻二酚鼻用制剂
ES2986160T3 (es) 2019-08-30 2024-11-08 Evie Sa Gránulos cargados, su proceso de producción y sus usos
GB2588455B (en) * 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
US11419800B2 (en) 2019-12-06 2022-08-23 JLABS Beauty LLC Topical compositions containing rose oil and cannabidiol and methods of making and using the same
TWI708835B (zh) * 2020-01-17 2020-11-01 和協工程股份有限公司 緩釋型釋碳凝膠基質及土壤整治方法
CH717205A1 (de) * 2020-03-11 2021-09-15 Jk Holding Gmbh Verwendung von Cannabinoiden in Therapie- und Wellnessgeräten.
US20210322343A1 (en) * 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders
EP4164613A4 (en) * 2020-06-20 2024-10-23 Chavan, Neha COMPOSITIONS FOR SOLUBILISING WATER-INSOLUBLE ACTIVE SUBSTANCES
EP3984522A1 (de) * 2020-10-19 2022-04-20 Shima Khaki Zusammensetzung, vorrichtung und verwendung
US12029720B2 (en) 2021-04-29 2024-07-09 Tilray Brands, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
IT202100014909A1 (it) * 2021-06-08 2022-12-08 Velleja Res S R L Formulazioni oleose di cannabinoidi
CN113304109A (zh) * 2021-06-08 2021-08-27 内蒙古大唐药业股份有限公司 一种醋柳黄酮固体脂质纳米粒分散液及其制备方法
WO2023028708A1 (en) * 2021-09-02 2023-03-09 Canopy Growth Corporation Water-soluble cannabinoid compositions, methods of making and use
US11471905B1 (en) 2021-09-23 2022-10-18 Apackaging Group Llc All plastic airless pump dispenser
EP4186490A1 (en) 2021-11-29 2023-05-31 Sanity Group GmbH Kit for preparing a medicament, cannabinoid composition, and preparation method
GB2634400A (en) * 2022-03-15 2025-04-09 Milehigh Repro Solutions Llc Methods and systems to reduce injury in treated tissues
KR20250008060A (ko) 2022-04-12 2025-01-14 섀클포드 파마 인코포레이티드 발작 장애의 치료
WO2024010628A1 (en) * 2022-07-05 2024-01-11 Poviva Corp Pharmaceutical compositions and methods for treating hypertension
US11666543B1 (en) * 2022-07-05 2023-06-06 Poviva Corp. Pharmaceutical compositions and methods for treating hypertension
US11980593B2 (en) 2022-07-05 2024-05-14 Poviva Corp. Compositions and methods for treating hypertension
WO2025024007A1 (en) * 2023-07-24 2025-01-30 Poviva Corp . Compositions and methods for treating epilepsy
WO2025140869A1 (en) * 2023-12-28 2025-07-03 Linnea Sa Process for stabilising a macerated oil

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
GB0103638D0 (en) * 2001-02-14 2001-03-28 Gw Pharmaceuticals Ltd Pharmaceutical formulations
GB2392093B (en) * 2002-08-14 2006-03-08 Gw Pharma Ltd Pharmaceutical formulations
CN101132781A (zh) * 2004-12-09 2008-02-27 茵西斯医疗公司 在室温下稳定的屈大麻酚剂型
US20070060639A1 (en) * 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
KR20240162608A (ko) * 2011-05-15 2024-11-15 에이세러스 바이오파마 인크. 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도

Also Published As

Publication number Publication date
WO2017208072A2 (en) 2017-12-07
EP3478270A4 (en) 2019-11-27
CN109789090A (zh) 2019-05-21
TWI790204B (zh) 2023-01-21
TW201801721A (zh) 2018-01-16
WO2017208072A3 (en) 2018-01-11
MX2018014978A (es) 2019-09-04
EP3478270A2 (en) 2019-05-08
CA3026274A1 (en) 2017-12-07
MX392668B (es) 2025-03-24
KR20190034506A (ko) 2019-04-02
BR112018075073A2 (pt) 2019-04-30
KR102433459B1 (ko) 2022-08-17
US20170348276A1 (en) 2017-12-07
CO2018013654A2 (es) 2019-08-30
UY37271A (es) 2017-11-30

Similar Documents

Publication Publication Date Title
CL2018003452A1 (es) Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides.
MX2020012041A (es) Formulacion farmaceutica.
MX383529B (es) Formulación de goma de mascar que comprende partículas de un agente farmacéutico del grupo de cannabinoides, derivados de cannabinoides, terpenos o una mezcla de los mismos.
CO2022002685A2 (es) Nanopartículas lipídicas mejoradas para el suministro de ácidos nucleicos
FI2887923T3 (fi) Polyoksylilipidin tai polyoksylirasvahapon oftalminen formulaatio ja silmätilojen hoito
MX2020007784A (es) Uso de cannabinoides en el tratamiento de la epilepsia.
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
CO2019005729A2 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
MX2018011278A (es) Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
PE20130216A1 (es) Formulacion topica para un inhibidor de jak
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
PE20191714A1 (es) Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso
PE20190318A1 (es) Composicion administrable oralmente
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
GT201300292A (es) Formulaciones peptídicas de liberación controlada.
MX391861B (es) Composiciones de canabinoide y usos
EA201691808A1 (ru) Кортикостероидные композиции для местного применения
NZ726746A (en) Stable cannabinoid formulations
NZ731248A (en) Cannabis extracts and methods of preparing and using same
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
MX2015012559A (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
MX2024010721A (es) Formulaciones topicas que contienen ciclosporina y usos de las mismas.
PE20171246A1 (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
CO2021005915A2 (es) Composiciones estables de semaglutida y usos de las mismas